- Home
- TFSL vs IOVA Comparison
TFSL vs IOVA Comparison
Compare TFSL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFSL
- IOVA
- Stock Information
- Founded
- TFSL 1938
- IOVA 2007
- Country
- TFSL United States
- IOVA United States
- Employees
- TFSL N/A
- IOVA N/A
- Industry
- TFSL Savings Institutions
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TFSL Finance
- IOVA Health Care
- Exchange
- TFSL Nasdaq
- IOVA Nasdaq
- Market Cap
- TFSL N/A
- IOVA 2.6B
- IPO Year
- TFSL 2007
- IOVA N/A
- Fundamental
- Price
- TFSL $12.50
- IOVA $5.89
- Analyst Decision
- TFSL Hold
- IOVA Strong Buy
- Analyst Count
- TFSL 3
- IOVA 9
- Target Price
- TFSL $14.33
- IOVA $23.33
- AVG Volume (30 Days)
- TFSL 275.1K
- IOVA 8.2M
- Earning Date
- TFSL 01-28-2025
- IOVA 02-26-2025
- Dividend Yield
- TFSL 9.09%
- IOVA N/A
- EPS Growth
- TFSL 7.69
- IOVA N/A
- EPS
- TFSL 0.28
- IOVA N/A
- Revenue
- TFSL $304,660,000.00
- IOVA $90,858,000.00
- Revenue This Year
- TFSL N/A
- IOVA $13,758.71
- Revenue Next Year
- TFSL $7.19
- IOVA $171.20
- P/E Ratio
- TFSL $44.64
- IOVA N/A
- Revenue Growth
- TFSL N/A
- IOVA 12751.20
- 52 Week Low
- TFSL $11.70
- IOVA $5.77
- 52 Week High
- TFSL $15.00
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- TFSL 41.09
- IOVA 26.25
- Support Level
- TFSL $12.06
- IOVA $5.77
- Resistance Level
- TFSL $12.75
- IOVA $8.15
- Average True Range (ATR)
- TFSL 0.23
- IOVA 0.44
- MACD
- TFSL -0.00
- IOVA -0.11
- Stochastic Oscillator
- TFSL 60.27
- IOVA 5.04
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.